secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001867096-23-000130
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris raises year-end cash guidance to $65-70M, tightens 2023 revenue to $155-165M
--------------------------------------------------------------------------------

- Year-end cash, equivalents, and short-term investments guided to $65-70M (up from $55-65M).
- Full-year 2023 total revenue guidance tightened to $155-165M from $145-165M.
- Received $6M milestone payment from Amgen for subcutaneous TEPEZZA formulation success.
- Company reaffirms cash flow breakeven in Q4 2023; net cash outflow H2 expected ~$11-16M.
- Q3 2023 earnings call scheduled for November 9, 2023 at 8:30 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000130/0001867096-23-000130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000130/xers-20231016.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer